Sandoz Rehashed Arguments In Rituxan IP Challenge: PTAB
The Patent Trial and Appeal Board rejected challenges from Sandoz Inc. to a patent covering Genentech Inc.'s biologic Rituxan after finding they were too similar to ones brought by another biosimilar...To view the full article, register now.
Already a subscriber? Click here to view full article